HBeAg seroconversion in HBV patients is considered an important event. We determined precore (PC) and base core promoter (BCP) mutations in 137 HBeAg-positive nucleos(t)ide analogues (NA) treated patients by INNO-LiPA HBV PreCore assay (Innogenetics). The majority of patients with nongenotype A had PC/BCP mutants present at baseline (P = 0.02). During 29 months of therapy, 45 patients achieved HBeAg seroconversion. Probability of HBeAg seroconversion was higher in patients with PC and/or BCP mutants (P = 0.01). After HBeAg seroconversion, patients with BCP mutants had more HBeAg relapse (P = 0.07), and PC mutants less often achieved HBV DNA < 2000 IU/mL (P = 0.07).

Additional Metadata
Keywords basal core promoter, hepatitis B surface Antigen, nucleos(t)ide analogues, precore
Persistent URL dx.doi.org/10.1111/jvh.12033, hdl.handle.net/1765/39922
Journal Journal of Viral Hepatitis
Zoutendijk, R, Sonneveld, M.J, Reijnders, J.G.P, van Vuuren, A.J, Biesta, P.J, Hansen, B.E, … Janssen, H.L.A. (2013). Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues. Journal of Viral Hepatitis, 20(5), 322–327. doi:10.1111/jvh.12033